VivoSeq
Other

Dyspareunia

6

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Dyspareunia is an early-stage landscape with 6 programs across 4 companies. The most active players are Teva, Novo Nordisk, Auxilium. 4 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Teva logo

Teva

1 program

Phase 3Novo Nordisk logo

Novo Nordisk

1 program

ApprovedA

Auxilium

1 program

ApprovedAlnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

8

clinical trials

Completed7 · 88%
Active, not recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

Physiotherapeutic Approach to Superficial and Deep Dyspareunia in Women With Chronic Pelvic Pain: Comparison Between In-person and Telehealth Care.
Active, not recruiting·UUniversity of Sao Paulo·Preclinical·NCT07658703·72 enrolled
Local DHEA and Estradiol on Dyspareunia in Postmenopausal Women
Completed·—·Phase 4·NCT05586711·170 enrolled
Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia
Completed·SSan Diego Sexual Medicine·Phase 4·NCT03568604·18 enrolled
Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy
Completed·Teva logoTeva·Phase 3·NCT05617820·1,050 enrolled
Treating Postmenopausal Dyspareunia Where it Hurts
Completed·OOregon Health and Science University·Phase 4·NCT03240081·50 enrolled
Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA
Completed·—·Phase 4·NCT02784613·10 enrolled
Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia
Completed·—·Phase 3·NCT01845649·550 enrolled
Postpartum Dyspareunia Resulting From Vaginal Atrophy
Completed·MMeir Medical Center·N/A·NCT01319968·117 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)